Clinical trial
Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
NCT00203424 · Translational Oncology Research International, Other · Completed
Key facts
| NCT number | NCT00203424 |
|---|---|
| Title | Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib |
| Official title | A Phase II Trial of Adjuvant Bevacizumab and Erlotinib in Patients at High Risk for Early Relapse Following Radical Prostatectomy for Prostate Cancer |
| Lead sponsor | Translational Oncology Research International, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Erlotinib + Bevacizumab |
| Enrollment | 23 |
| Start date | Jan 1, 2006 |
| Primary completion | Feb 1, 2009 |
| Completion | Jun 1, 2010 |
| First posted | Sep 20, 2005 |
| Last update posted | Mar 25, 2016 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: